1	S.220
2	Senators Lyons, Cummings, Ingram, McCormack and Westman move that
3	the report of the Committee on Government Operations be amended as
4	follows:
5	First: In Sec. 11, 26 V.S.A. chapter 36 (pharmacy), in section 2023 (clinical
6	pharmacy; prescribing), in subdivision (a)(2), following "prescribe a biological
7	product as defined in 18 V.S.A. § 4601, other than" by striking out "a vaccine
8	or insulin medication; or" and inserting in lieu thereof an insulin medication,
9	an influenza vaccine or vaccine to mitigate a significant public health risk, or,
10	pursuant to a collaborative practice agreement, another vaccine; or
11	Second: In Sec. 11, 26 V.S.A. chapter 36 (pharmacy), in section 2023
12	(clinical pharmacy; prescribing), in subdivision (b)(2)(A), by striking out
13	subdivisions (vii) and (viii) in their entireties and inserting in lieu thereof the
14	following:
15	(vii) influenza vaccines;
16	(viii) in the event of a significant public health risk, an appropriate
17	vaccine to mitigate the effects on public health after finding that existing
18	channels for vaccine administration are insufficient to meet the public health
19	need; and
20	(ix) emergency prescribing of albuterol or glucagon while
21	contemporaneously contacting emergency services.

(Draft No. 4.1 – S.220) 6/3/2020 – BAW/JGC – 10:54 AM

1	Third: In Sec. 16, 26 V.S.A. chapter 57 (review of regulatory laws), in
2	section 3108 (preliminary assessment of scope of practice), in subdivision
3	(a)(1), following "and upon the request of the House or Senate Committee on
4	Government Operations" by inserting or, in the case of a health care
5	profession, the House Committee on Health Care or the Senate Committee on

6 <u>Health and Welfare</u>,